A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 04 05 2018
accepted: 12 10 2018
pubmed: 21 10 2018
medline: 22 6 2019
entrez: 21 10 2018
Statut: ppublish

Résumé

Despite the widespread use of 5-HT

Identifiants

pubmed: 30341536
doi: 10.1007/s00520-018-4515-4
pii: 10.1007/s00520-018-4515-4
doi:

Substances chimiques

Antiemetics 0
Aprepitant 1NF15YR6UY

Types de publication

Clinical Trial, Phase II Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2295-2300

Références

Biol Blood Marrow Transplant. 2001;7(11):596-603
pubmed: 11760147
Cancer. 2003 Jun 15;97(12):3090-8
pubmed: 12784346
J Clin Oncol. 2003 Nov 15;21(22):4112-9
pubmed: 14559886
J Clin Oncol. 2005 Feb 20;23(6):1289-94
pubmed: 15718327
Cancer. 2005 May 15;103(10):2082-90
pubmed: 15830348
J Clin Oncol. 2005 Apr 20;23(12):2822-30
pubmed: 15837996
J Clin Oncol. 2006 Sep 20;24(27):4472-8
pubmed: 16983116
J Cell Physiol. 1991 Jul;148(1):60-7
pubmed: 1860896
J Clin Oncol. 2012 Nov 10;30(32):3998-4003
pubmed: 22915652
J Clin Oncol. 2014 Oct 20;32(30):3413-20
pubmed: 25225424
Int J Hematol. 2015 Apr;101(4):376-85
pubmed: 25644148
Biomed Res Int. 2015;2015:497597
pubmed: 25654108
Ann Oncol. 2016 Sep;27(suppl 5):v119-v133
pubmed: 27664248
Haematologica. 2018 Jun;103(6):988-998
pubmed: 29519869
Br J Cancer. 1997;76(8):1055-61
pubmed: 9376266

Auteurs

Joseph M Brandwein (JM)

Division of Hematology, Department of Medicine, University of Alberta, 11350 - 83 Ave., Suite 4-112 CSB, Edmonton, AB, T6G 2G3, Canada. jbrandwe@ualberta.ca.

Jack T Seki (JT)

Pharmacy Department, Princess Margaret Cancer Centre, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.

Eshetu G Atenafu (EG)

Biostatistics Department, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Amr Rostom (A)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Andrzej Lutynski (A)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Anna Rydlewski (A)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Aaron D Schimmer (AD)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Andre C Schuh (AC)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Vikas Gupta (V)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Karen W L Yee (KWL)

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH